Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.

Abstract: Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors more than 150 proteins to the cell surface. Pathogenic variants in several genes that participate in GPI biosynthesis cause inherited GPI deficiency (IGD) disorders. Here, the inventors reported that homozygous null alleles of PIGG, a gene involved in GPI modification, are responsible for the rare Emm-negative blood phenotype. Using a panel of K562 cells defective in both the GPI-transamidase and GPI remodeling pathways, they demonstrate that the Emm antigen, whose molecular basis has remained unknown for decades, is carried only by free GPI and that its epitope is composed of the second and third ethanolamine of the GPI backbone. Importantly, the inventors show that the decrease in Emm expression in several IGD patients is indicative of GPI defects. Overall, our findings establish Emm as a novel blood group system and have important implications for understanding the biological function of human free GPI.

Abstract: Suggested is an active mixture, comprising or consisting of: (a) at least one biopolymer; (b) at least one glycosaminoglycan; (c) at least one disaccharide; and optionally (d) at least one active selected from the group consisting of phenols and/or polyphenols.

Abstract: The present invention provides methods to personalise dietary fiber for an individual based on their CAZyme profile and recommendations for dietary fiber products and compositions as well as systems to facilitate quick and easy use.

Abstract: A connecting device including first and second off-center rings, the second ring being positioned in the first ring. The peripheral outer surface of the first ring is frustoconical and has a smaller cross section oriented in a first direction, and the inner surface of the first ring and the outer surface of the second ring, which surfaces interact with one another, have cross sections which increase between a first cross section and a second cross section that is offset in relation to the first cross section in an opposite direction to the first direction. This arrangement makes it possible to be able to prevent the rotation of the first and second rings once their angular positioning has been adjusted.

Abstract: The present disclosure provides materials and methods for the treatment of autoimmune diseases (including vitiligo).

Abstract: Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).

Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; the composition is systemically administered.

Abstract: Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).

Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; the composition is systemically administered.

Abstract: According to the present invention, an extract is obtained from the Globularia genus is obtained from a plant of the genus Globularia and is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used for preventing and/or treating skin ageing by stimulating the reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.

Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; the composition is systemically administered.

Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: —the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; —the composition is systemically administered.

Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18-19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase dermo-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.

Abstract: The extract of plant origin is characterized in that it is obtained from a plant of the genus Globularia, preferably the species Globularia Cordifolia. The extract according to the invention can be obtained by in vitro plant culture of undifferentiated cells. It can be used as an active agent in a composition for preventing and/or treating skin aging by stimulating detoxification reactions and cellular regeneration thanks to a hormetic type response. With such a composition, improvement of the visual appearance of the skin, radiance and transparency of complexion is obtained for example.

Abstract: According to the present invention the extract of plant origin of the Globularia genus is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used in particular for preventing and/or treating skin ageing by stimulating the 10 reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for 15 preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.

Abstract: Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).

Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.

Abstract: A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein:—the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;—the composition is systemically administered.

Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18-19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase dermo-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.